Skip to main content

Table 4 EGFR and ERBB2 quantitative RT-PCR mRNA results in eight patients and matched controls (group B)

From: Increased copy number at 3p14 in breast cancer

Patient number T NN T/NNa
1b    
EGFR 4,677 12,493 0.37
ERBB2 24,066 21,817 1.1
2b    
EGFR 3,321 14,519 0.22
ERBB2 61,389 6,666 9.2
4    
EGFR 20,778 14,842 1.39
ERBB2 9,143 6,742 1.35
5b    
EGFR 9,730 15,867 0.61
ERBB2 13,506 3,056 4.41
6    
EGFR 1,305 15,871 0.08
ERBB2 10,677 10,080 1.06
7    
EGFR 1,024 12,162 0.08
ERBB2 7,639 5,871 1.30
8b    
EGFR 4,936 28,111 0.17
ERBB2 17,106 9,263 1.85
9    
EGFR 5,540 1,437 3.85
ERBB2 7,330 5,540 1.32
  1. aT/NN: mRNA expression levels of LRIG1 in tumour tissue (T) samples divided by values in matched non-neoplastic (NN) tissue samples. As described in the results, at p.9, ratios >1. 2 are regarded as significant overexpression and ratios <0. 8 are regarded as significant underexpression in neoplastic tissue compared to non-neoplastic tissue. bPatients with increased LRIG1 copy number. No RNA from patient 3 was available for EGFR/ERBB2 analysis.